Claudio Feliciani
A5017615796- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Lysosomal Storage Disorders Research
- Nail Diseases and Treatments
- Cutaneous lymphoproliferative disorders research
- Cutaneous Melanoma Detection and Management
- Dermatologic Treatments and Research
- Cancer and Skin Lesions
- melanin and skin pigmentation
- Acne and Rosacea Treatments and Effects
- Genetic and rare skin diseases.
- Nonmelanoma Skin Cancer Studies
- Hair Growth and Disorders
- Immunotherapy and Immune Responses
- Allergic Rhinitis and Sensitization
- Platelet Disorders and Treatments
- Drug-Induced Adverse Reactions
- Contact Dermatitis and Allergies
- Skin Protection and Aging
- Asthma and respiratory diseases
- Autoimmune and Inflammatory Disorders
- Oral Health Pathology and Treatment
University of Parma
2016-2025
The University of Tokyo
2024
Bunkyo University
2024
Ospedale di Parma
2016-2023
Marconi University
2019-2022
Hanoi Medical University
2022
Städtisches Klinikum Dresden
2022
Oxfam
2022
John Wiley & Sons (United States)
2022
John Wiley & Sons (United Kingdom)
2022
Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, oral pharmacologic chaperone, stabilizes specific mutant forms α-galactosidase, increasing enzyme trafficking lysosomes.The initial assay that we used categorize 67 patients with disease for randomization 6 months double-blind migalastat or placebo (stage 1), followed by open-label from 12 2) plus additional year, had certain limitations. Before...
Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of skin and mucous membranes. This typically affects elderly presents with itch localized or generalized bullous lesions. In up to 20% affected patients, bullae may be completely absent, only excoriations, prurigo‐like lesions, eczematous urticated lesions and/or infiltrated plaques are observed. The significantly associated neurological disorders. morbidity its impact on quality life significant. So far, a...
Abstract Background Pemphigus encompasses a group of life‐threatening autoimmune bullous diseases characterized by blisters and erosions the mucous membranes skin. Before era immunosuppressive treatment, prognosis pemphigus was almost fatal. Due to its rarity, only few prospective controlled therapeutic trials are available. Objectives For this reason, European dermatologists with long‐standing interest expertise in basic clinical research has sought define diagnostic guidelines for...
Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions the mucous membranes skin. Before era immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate severe vulgaris in Europe United States.The Autoimmune blistering Task Force European Academy Dermatology Venereology...
Abstract Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of skin and mucous membranes. This typically affects elderly presents with itch localized or, frequently, generalized bullous lesions. A subset patients only develops excoriations, prurigo‐like lesions, eczematous and/or urticarial erythematous The disease, which significantly associated neurological disorders, has high morbidity severely impacts quality life. Objectives methodology...
This guideline has been initiated by the task force Autoimmune Blistering Diseases of European Academy Dermatology and Venereology, including physicians from all relevant disciplines patient organizations. It is a S3 consensus-based that systematically reviewed literature on mucous membrane pemphigoid (MMP) in MEDLINE EMBASE databases until June 2019, with no limitations language. While first part this addressed methodology, as well epidemiology, terminology, aetiology, clinical presentation...
Abstract This guideline on mucous membrane pemphigoid (MMP) has been elaborated by the Task Force for Autoimmune Blistering Diseases of European Academy Dermatology and Venereology (EADV) with a contribution physicians from all relevant disciplines patient organizations. It is S3 consensus‐based encompassing systematic review literature until June 2019 in MEDLINE EMBASE databases. first part covers methodology, clinical definition MMP, epidemiology, MMP subtypes, immunopathological...
SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of present guideline on systemic treatment chronic plaque psoriasis. With permission EuroGuiDerm, adapted Italian healthcare context supply a reliable and affordable tool physicians who take care patients affected by moderate severe The content includes general information scope purpose, health questions covered, target users strength/limitations...
Abstract Background Paraneoplastic pemphigus (PNP), also called paraneoplastic autoimmune multiorgan syndrome (PAMS), is a rare disease with mucocutaneous and multi‐organ involvement. PNP/PAMS typically associated lymphoproliferative or haematological malignancies, less frequently solid malignancies. The mortality rate of elevated owing to the increased risk severe infections disease‐associated complications, such as bronchiolitis obliterans. Objectives These guidelines summarize...
The migration of epidermal Langerhans cells (LC) to lymph nodes (LN) is critical in the initiation contact hypersensitivity (CHS) responses. Studies suggest that allergen-induced proinflammatory cytokines, including IL-1 and TNF-alpha, play important roles promoting LC migration. Contact allergens also induce anti-inflammatory cytokines such as IL-10. Since IL-10 down-regulates cytokine production inhibits CHS, we hypothesized might inhibit To test this hypothesis, knockout (KO) mice were...
Cerebral inflammation as well systemic immunological alterations has been reported in Alzheimer's disease (AD). We aimed to determine whether spontaneous and mitogen stimulated production of peripheral blood mononuclear cell (PBMC) cytokines, chem
Two pemphigus severity scores, Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI), have been proposed to provide an objective measure of disease activity. However, the use these scores in clinical practice is limited by absence cut‐off values that allow differentiation between moderate, significant extensive types pemphigus. To calculate defining based on ABSIS PDAI scores. In 31 dermatology departments six countries, consecutive patients with...
Alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles.The course unpredictable and current available treatments have variable efficacy.Nowadays, there relatively little evidence on treatment of AA from well-designed clinical trials.Moreover, none the or devices commonly used to treat are specifically approved by Food Drug Administration.The italian Study Group for Cutaneous annexial disease Society dermatology proposes these guidelines diagnosis
Abstract Introduction Dermatitis herpetiformis (DH) is a chronic, pruritic, gluten‐induced skin disorder characterized by subepidermal granular IgA deposition and variable degree of enteropathy identical to that seen in coeliac disease. So far, there has been no European consensus about the management DH. Methods The guidelines were created small subgroups guideline committee consisting 26 specialists from various medical fields one patients’ representative. members then discussed voted for...
Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age their side-effects. Dupilumab was recently adolescent AD.A multicentre, prospective, real-world study on effectiveness safety dupilumab adolescents (aged from ≥12 <18 years) with moderate-to-severe AD conducted. The main clinical phenotypes were also examined.Data treated at label dosage 16 weeks collected....